Marcus  Schulz net worth and biography

Marcus Schulz Biography and Net Worth

Marcus Schulz  started at BioLife in 2020 as Vice President of Global Sales and was promoted to Chief Revenue Officer in 2021. He brings 20 years of healthcare experience to the Biolife executive leadership team.

Prior to joining BioLife in 2019, Marcus served in a variety of strategic business development and executive sales leadership roles with such leading companies as Siemens Healthcare, Johnson & Johnson, Abbott Laboratories and most recently, GE Healthcare. Marcus consistently delivers exceptional results, driving record revenues and growing market share in highly competitive and complex market segments.

He thinks of himself as a customer advocate and takes pride in building strong, lasting relationships through an in-depth understanding of each customer’s unique needs. He excels at identifying and nurturing talent and developing and leading strong teams. Marcus holds a B.A. from Villanova University.

What is Marcus Schulz's net worth?

The estimated net worth of Marcus Schulz is at least $1.12 million as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $1,122,727 as of February 22nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.

How do I contact Marcus Schulz?

The corporate mailing address for Mr. Schulz and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at rdegreef@biolifesolutions.com. Learn More on Marcus Schulz's contact information.

Has Marcus Schulz been buying or selling shares of BioLife Solutions?

Marcus Schulz has not been actively trading shares of BioLife Solutions during the past quarter. Most recently, Marcus Schulz sold 347 shares of the business's stock in a transaction on Friday, August 25th. The shares were sold at an average price of $10.99, for a transaction totalling $3,813.53. Following the completion of the sale, the executive now directly owns 42,097 shares of the company's stock, valued at $462,646.03. Learn More on Marcus Schulz's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, insiders at the medical equipment provider sold shares 68 times. They sold a total of 179,217 shares worth more than $3,860,661.93. The most recent insider tranaction occured on February, 12th when EVP Aby J Mathew sold 92 shares worth more than $2,441.68. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 2/12/2025.

Marcus Schulz Insider Trading History at BioLife Solutions

Marcus Schulz Buying and Selling Activity at BioLife Solutions

This chart shows Marcus Schulz's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $26.67
Low: $26.42
High: $27.90

50 Day Range

MA: $26.93
Low: $24.98
High: $28.49

2 Week Range

Now: $26.67
Low: $14.50
High: $29.55

Volume

259,865 shs

Average Volume

238,085 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91